(S)-3-{[2-(4-Cyano-phenyl)-1H-benzoimidazole-5-carbonyl]-amino}-N-phenethyl-succinamic acid methyl ester | 175402-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (S)-3-{[2-(4-Cyano-phenyl)-1H-benzoimidazole-5-carbonyl]-amino}-N-phenethyl-succinamic acid methyl ester
• CAS: 175402-00-3
• 化学式: C₂₈H₂₅N₅O₄
• 分子量: 495.538
• InChiKey: KYZIVWHTTHXTDC-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.12
• 重原子数：
  37.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  136.97
• 氢给体数：
  3.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  (S)-3-{[2-(4-Cyano-phenyl)-1H-benzoimidazole-5-carbonyl]-amino}-N-phenethyl-succinamic acid methyl ester 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (3S)-3-[[2-[4-(aminomethyl)phenyl]-3H-benzimidazole-5-carbonyl]amino]-4-oxo-4-(2-phenylethylamino)butanoic acid
  参考文献：
  名称：

  Design, synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors

  摘要：

  A potent centrally constrained series of benzimidazole and benzoxazole glycoprotein IIb/IIIa inhibitors has been discovered based on the solution conformation of a cyclic RGD-containing peptide, DMP 728. The high potency of this series of compounds in the inhibition of platelet aggregation requires a benzamidine as the basic moiety and an alpha-carbamate or sulfonamide substituted beta-alanine as the acidic moiety.

  DOI：

  10.1016/0960-894x(95)00590-p
• 作为产物：
  描述：

  3,4-二氨基苯甲酸 在 molecular sieve 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (S)-3-{[2-(4-Cyano-phenyl)-1H-benzoimidazole-5-carbonyl]-amino}-N-phenethyl-succinamic acid methyl ester
  参考文献：
  名称：

  Design, synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors

  摘要：

  A potent centrally constrained series of benzimidazole and benzoxazole glycoprotein IIb/IIIa inhibitors has been discovered based on the solution conformation of a cyclic RGD-containing peptide, DMP 728. The high potency of this series of compounds in the inhibition of platelet aggregation requires a benzamidine as the basic moiety and an alpha-carbamate or sulfonamide substituted beta-alanine as the acidic moiety.

  DOI：

  10.1016/0960-894x(95)00590-p